IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9187515 B1

PDFFull Text
Date of Patent:
Nov. 17, 2015

Filed:

Apr. 01, 2014

2',4′-fluoro nucleosides for the treatment of hcv

Applicant:

Idenix Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Benjamin Alexander Mayes, Boston, MA (US);

Adel M. Moussa, Burlington, MA (US);

Alistair James Stewart, Lincoln, MA (US);

Assignee:

IDENIX PHARMACEUTICALS LLC, Cambridge, MA (US);

Attorneys:

Jeffrey P. Bergman

Laura M. Ginkel

Primary Examiner:

Traviss C McIntosh, III

Int. Cl.
CPC ...
C07H 19/16 (2006.01); C07H 19/048 (2006.01); C07H 19/10 (2006.01); C07H 19/20 (2006.01); C07H 19/06 (2006.01); A61K 31/7072 (2006.01); A61K 31/7068 (2006.01); A61K 31/708 (2006.01); A61K 45/06 (2006.01); A61K 31/7076 (2006.01); A61K 38/21 (2006.01); A61K 31/403 (2006.01); A61K 31/4184 (2006.01); A61K 31/4709 (2006.01); A61K 31/497 (2006.01);
U.S. Cl.
CPC ...
C07H 19/16 (2013.01); A61K 31/403 (2013.01); A61K 31/4184 (2013.01); A61K 31/4709 (2013.01); A61K 31/497 (2013.01); A61K 31/708 (2013.01); A61K 31/7068 (2013.01); A61K 31/7072 (2013.01); A61K 31/7076 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 45/06 (2013.01); C07H 19/048 (2013.01); C07H 19/06 (2013.01); C07H 19/10 (2013.01); C07H 19/20 (2013.01);
Abstract

Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2',4′-fluoro nucleosides according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, R, and PD are as described herein. In certain embodiments, 2′,4′-fluoro nucleosides are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.

Find Patent Forward Citations

Loading…